David & Goliath: AstraZeneca versus Hikma Pharmaceuticals

Which company is most attractive, AstraZeneca or its smaller rival Hikma Pharmaceuticals?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

astrazenecaBig cap FTSE 100 shares are ever popular, but I sometimes wonder whether looking down the food chain, perhaps at companies in the FTSE 250 index, could produce an investment idea that’s equally solid, but with potentially more exciting forward prospects.

To test the theory, I’m contrasting AstraZeneca (LSE: AZN) (NYSE: AZN.US) with its far smaller rival Hikma Pharmaceuticals (LSE: HIK). AstraZeneca’s £48,420 million market capitalisation makes it 20 times the size of Hikma Pharmaceuticals, with its £2,407 million valuation. That David-and-Goliath situation underlines the success that AstraZeneca has enjoyed and suggests that Hikma Pharmaceuticals has plenty of room to grow.

The business models

The companies have different business models. AstraZeneca spends millions on research & development to generate a pipeline of patent-protected drugs, which it then markets exclusively for a premium sales price. In recent years, however that strategy has been problematic — many best-selling products have timed-out on patent protection, losing their ‘exclusivity’ and allowing generic competition to enter the market, which has stymied earnings’ growth.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Hikma Pharmaceuticals is one of the companies that compete by producing generic drugs once a product’s exclusivity has lapsed. The firm also deals with in-licensed pharmaceutical products, providing the marketing and distribution expertise and resources for products developed by other firms.

Both AstraZeneca and Hikma Pharmaceuticals count their product offerings in the hundreds. AstraZeneca’s biggest market is the US with around 38% of sales, followed by Western Europe with 23%, Emerging Markets with 21% and 18% from the rest of the world. Hikma Pharmaceuticals sells 56% of its goods to the Middle East and North Africa, 36% to the US, and 8% to Europe and the rest of the world.

Growth records

The two strategies have produced different financial outcomes. AstraZeneca has achieved a compound annual growth rate (CAGR) of 3.5% for earnings per share over the last five years. That’s supported a CAGR of 6.4% for the dividend. Hikma Pharmaceuticals has done better with a CAGR of 11.3% for earnings supporting 16.4% annualised growth in the dividend over the same five-year period.

City analysts expect AstraZeneca’s earnings to fall by 24% for 2013, then down a further 10% in 2014 and come in flat for 2015. That contrasts with Hikma Pharmaceuticals, which they expect to achieve earnings growth of 80% for 2013, then down 13% for 2014, but up 12% in 2015.

Hikma pharmaceuticals is the clear winner on forward earnings’ growth prospects.

Valuations

At today’s 3,906p share price, AstraZeneca’s forward P/E ratio is running at about 15 for 2015. For that, investors tap into a 4.4% forward dividend yield with the payout covered about 1.5 times by forward earnings.

Meanwhile, at a share price of 1213p, Hikma Pharmaceutical’s P/E ratio is at 18.5 for 2015. Earnings cover the forward dividend 3.5 times and the forward yield is 1.5%.

What now?

AstraZeneca looks good for its dividend but, given its lacklustre growth outlook, I find Hikma Pharmaceuticals valuation and prospects more attractive and I think the firm is a good candidate for further research with a view to buying on share-price dips.

This AI stock is becoming a digital juggernaut in a £ 12.5 billion market!

🤖 Curious about the next big player in AI? 🤖

Our leading industry analysts have uncovered a trailblazing content platform that's revolutionising the industry with its unparalleled generative AI technology, setting new standards in creativity and efficiency.

Care for a sneak peek?

Trusted by global giants like Amazon, Disney, and Netflix, this innovative company is not just transforming digital media with AI-generated 3D content but is also capturing a significant share of a £12.7 billion market!

With a remarkable 62% gross margin, indicating exceptional profitability and operational efficiency, this company's growth trajectory positions it as a must-watch for savvy investors.

Best of all, we're offering exclusive access to the name of this game-changing stock, absolutely free!

Discover your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin does not own shares in AstraZeneca or Hikma .

More on Investing Articles

Senior woman potting plant in garden at home
Investing Articles

Why I prefer investing with Warren Buffett to a FTSE 100 or S&P 500 tracker

When it comes to buying shares, ignoring advice from Warren Buffett is rarely a good idea. But our author thinks…

Read more »

Investing Articles

Forget gold! I prefer UK shares for trying to build long-term wealth

Stock market volatility has sent investors running to safe-haven assets. But for building wealth over time, Stephen Wright prefers UK…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

This S&P 500 stock looks crazily mispriced to me

After hitting a record high on 4 February, this S&P 500 stock crashed hard during the 'Trump slump'. But even…

Read more »

Investing Articles

Meet the FTSE 100 share I’m happy to own, even during the next recession

This FTSE 100 giant was founded in 1929, just before the Great Depression devastated the global economy. Today, it is…

Read more »

Investing Articles

£10,000 invested in NatWest shares 10 years ago is now worth this much

NatWest shares have surged over the past year, but the last decade hasn’t been overly kind to the bank and…

Read more »

Investing Articles

Is Nvidia stock undervalued? Here’s what the charts say

Nvidia stock has slumped on the back of technological developments out of China and Trump’s trade policy. Dr James Fox…

Read more »

Investing Articles

Up 20% in a month, should investors consider buying Marks & Spencer shares?

Shares in retailer Marks and Spencer have surged ahead over the last month, despite a cyberattack. Roland Head takes a…

Read more »

Charticle

Here are the latest growth and share price targets for Nvidia stock

Ben McPoland checks out the latest forecasts for Nvidia stock to assess whether it might be worth considering for a…

Read more »